Terasaki Institute
Terasaki Institute for Biomedical Innovation is a Los Angeles-based non-profit biomedical research institute developing advanced platforms including an AI-enabled smart contact lens for glaucoma, silk-kudzu hydrogels for wound closure, organoid-on-a-chip systems, and glioma classification frameworks, serving patients and academic researchers.
- Company typePrivate
- Founded2000
- HeadquartersLos Angeles, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Terasaki Institute firmographics
Firmographics- Name
- Terasaki Institute
- Legal name
- Terasaki Institute for Biomedical Innovation
- Website
- https://terasaki.org
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Terasaki Institute for Biomedical Innovation is a Los Angeles-based non-profit biomedical research institute developing advanced platforms including an AI-enabled smart contact lens for glaucoma, silk-kudzu hydrogels for wound closure, organoid-on-a-chip systems, and glioma classification frameworks, serving patients and academic researchers.
- Ownership category
- akta.pro rank
Where Terasaki Institute is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Markets served
Terasaki Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Distribution channels1 record
Marketing channels2 records
Terasaki Institute product offering
Product offeringCore offering
The Terasaki Institute for Biomedical Innovation is a non-profit research institute that develops proprietary biomedical technologies across biomaterials, organ-on-a-chip platforms, AI-enabled medical devices, and drug delivery systems. Its outputs include published research frameworks, prototype devices such as the AI-enabled smart contact lens for glaucoma management, silk-kudzu injectable hydrogels for wound closure, and tissueoid-on-a-chip platforms. These innovations are primarily disseminated through peer-reviewed publications and academic partnerships, with selected technologies advancing toward clinical trials and licensing.
Product overview
The Terasaki Institute for Biomedical Innovation is a research institute that develops biomedical innovations primarily as research outputs rather than commercial products. Their portfolio includes the AI-Enabled Smart Contact Lens for continuous glaucoma monitoring and drug delivery, the Silk-Kudzu Hydrogel for wound closure, the Glioma Organoid Model Framework for cancer research classification, and the Vascularized Liver Tissueoid-on-a-Chip system for tissue regeneration and transplant rejection studies. These products represent innovative biomedical research technologies published in peer-reviewed journals.
Differentiator
Problem solved
Functional benefit
Products and services
- AI-Enabled Smart Contact Lens for Glaucoma Monitoring A wearable medical device that continuously monitors intraocular pressure and delivers targeted drug therapy in a closed-loop system for glaucoma patients. Integrates soft-polymer sensors, AI algorithms, and responsive drug release with no electronic components, batteries, or metal sensors.
- Silk-Kudzu Hydrogel An injectable hydrogel synthesized from silk fibroin and puerarin (kudzu-derived) designed for wound sealing and soft tissue repair. Five formulations tested achieved complete wound closure within 72 hours in laboratory tests on human skin cells with over 95% cell viability and no observed toxicity.
- Glioma Organoid Model Framework
Quantifiable outcome
- Complete wound closure achieved within 72 hours in laboratory tests on human skin cells
- +4 more outcomes
Companies that use Terasaki Institute
Customer profileSegments4 records
Ideal customer profiles4 records
Terasaki Institute technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Terasaki Institute partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Hong Kong University of Science and TechnologycoreAn international research collaboration involving the Terasaki Institute in the United States and Hong Kong University of Science and Technology to jointly develop the smart contact lens for glaucoma patients. The lens detects intraocular pressure changes in real time and automatically releases medication, with results published in Science Translational Medicine.
- Keck Graduate Institute (KGI)coreA three-year collaborative research partnership between TIBI and Keck Graduate Institute established to accelerate biomedical innovation through joint research programs, faculty collaboration, and expanded student training opportunities. The agreement establishes a framework for interdisciplinary research across biomaterials, cell engineering, drug delivery, medical devices, and personalized medicine, with reciprocal access to laboratory infrastructure and facilities. The partnership also creates new opportunities for PhD student training and joint grant proposals, guided by a Collaborative Research Steering Committee.
Recent moves6 records
Expansion highlights5 records
Terasaki Institute competitors and assessment
Company assessmentEmerging players
- TissUse GmbH: Berlin-based developer of multi-organ-on-chip systems (Humimic) for toxicology and disease modeling. Comparable niche player in the same organ-on-chip space as TIBI's vascularized liver and immune-response platforms.
- Mimetas: Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models. Comparable to TIBI's tissueoid-on-a-chip work as a focused commercial player in the same microphysiological systems category.
- Integra LifeSciences: Developer and manufacturer of regenerative wound care and surgical implant products. Comparable commercial counterpart for TIBI's silk-kudzu injectable hydrogel, with established hospital and wound-care channels for licensing a soft-tissue repair platform.
Direct peers
- Emulate Inc. Commercial organ-on-chip platform (Liver-Chip, Lung-Chip) for preclinical drug development. Direct comparable for TIBI's vascularized liver tissueoid-on-a-chip and anti-cancer immunity organ-on-chip programs.
- CN Bio Innovations: Provider of single- and multi-organ organ-on-chip systems (PhysioMimix) for toxicology and disease modeling. Directly comparable to TIBI's microphysiological system portfolio and a likely licensing partner for chip-based platforms.
- Sensimed (iCare): Developer of the Triggerfish smart contact lens for continuous 24-hour intraocular pressure monitoring in glaucoma. Direct product-line competitor to TIBI's AI-enabled smart contact lens, with a CE-marked device already in clinical use across Europe.
- Gladstone Institutes: San Francisco-based independent biomedical research organization affiliated with UCSF, focused on translational research in cardiovascular, neurological, and infectious disease. Closely comparable to TIBI as a non-profit, independent, translational biomedical research institute of similar scale.
- Wyss Institute for Biologically Inspired Engineering: Harvard-affiliated translational research institute advancing biomaterials, organ-on-chip, and therapeutic device platforms. Closely comparable to TIBI as a non-university-administered biomedical innovation hub with parallel programs in hydrogels, microphysiological systems, and smart drug delivery.
Broad incumbents
- Alcon: Global ophthalmic device and pharmaceutical leader with extensive glaucoma franchise (drops, surgical devices). Broad incumbent whose glaucoma treatment portfolio TIBI's smart contact lens would complement or compete against.
- Johnson & Johnson Vision: Major ophthalmic device franchise spanning contact lenses, surgical, and pharmaceutical products. Relevant broad incumbent due to its scale in contact lens manufacturing and glaucoma therapeutics, positioning it as a likely commercialization partner for TIBI's smart lens.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key highlights7 records
Customer concentration
Terasaki Institute social profiles
Digital presenceTerasaki Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Terasaki Institute leadership team
Management profileNumber of profiles
Profiles2 records
Terasaki Institute funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Terasaki Institute M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Terasaki Institute
What does Terasaki Institute do?
The Terasaki Institute for Biomedical Innovation is a non-profit research institute that develops proprietary biomedical technologies across biomaterials, organ-on-a-chip platforms, AI-enabled medical devices, and drug delivery systems. Its outputs include published research frameworks, prototype devices such as the AI-enabled smart contact lens for glaucoma management, silk-kudzu injectable hydrogels for wound closure, and tissueoid-on-a-chip platforms. These innovations are primarily disseminated through peer-reviewed publications and academic partnerships, with selected technologies advancing toward clinical trials and licensing.
Is Terasaki Institute a public or private company?
Terasaki Institute is a private company. It is classified as unknown and is currently operating.
When was Terasaki Institute founded?
Terasaki Institute was founded in 2000. It employs 51 to 100 people.
Where is Terasaki Institute based?
Terasaki Institute is headquartered in Los Angeles, United States, in the North America region.
Who are Terasaki Institute's main competitors?
Emerging players on record are TissUse GmbH, Mimetas and Integra LifeSciences. Direct peers are Emulate Inc., CN Bio Innovations, Sensimed (iCare), Gladstone Institutes and Wyss Institute for Biologically Inspired Engineering. Broad incumbents are Alcon and Johnson & Johnson Vision.
Does Terasaki Institute have an API?
No public API is recorded for Terasaki Institute.